153 related articles for article (PubMed ID: 35336054)
1. Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer.
Vora D; Dandekar A; Bhattaccharjee S; Singh ON; Agrahari V; Peet MM; Doncel GF; Banga AK
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35336054
[TBL] [Abstract][Full Text] [Related]
2. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
Ahmed OA; Badr-Eldin SM
Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253
[TBL] [Abstract][Full Text] [Related]
3. Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration.
Alves GL; Teixeira FV; da Rocha PBR; Krawczyk-Santos AP; Andrade LM; Cunha-Filho M; Marreto RN; Taveira SF
Drug Deliv Transl Res; 2022 Mar; 12(3):526-537. PubMed ID: 33682031
[TBL] [Abstract][Full Text] [Related]
4. Formulation design and development of matrix diffusion controlled transdermal drug delivery of glimepiride.
Akram MR; Ahmad M; Abrar A; Sarfraz RM; Mahmood A
Drug Des Devel Ther; 2018; 12():349-364. PubMed ID: 29503528
[TBL] [Abstract][Full Text] [Related]
5. Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.
O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Wolthers T; Davis SR
Climacteric; 2003 Dec; 6(4):347-53. PubMed ID: 15006256
[TBL] [Abstract][Full Text] [Related]
6. Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment.
Nagai N; Ogata F; Otake H; Nakazawa Y; Kawasaki N
Int J Nanomedicine; 2018; 13():5215-5229. PubMed ID: 30233182
[TBL] [Abstract][Full Text] [Related]
7. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D
Menopause; 2004; 11(2):167-75. PubMed ID: 15021446
[TBL] [Abstract][Full Text] [Related]
8. Development and evaluation of a drug-in-adhesive transdermal delivery system for delivery of olanzapine.
Vora D; Banga AK
Expert Opin Drug Deliv; 2022 Nov; 19(11):1539-1548. PubMed ID: 36242524
[TBL] [Abstract][Full Text] [Related]
9. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies.
Gupta T; Kenjale P; Pokharkar V
Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of transdermal delivery system of tranylcypromine for the treatment of depression.
Shrestha N; Banga AK
Drug Deliv Transl Res; 2023 Apr; 13(4):1048-1058. PubMed ID: 36482163
[TBL] [Abstract][Full Text] [Related]
11. Development of matrix patches for transdermal delivery of a highly lipophilic antiestrogen.
Funke AP; Günther C; Müller RH; Lipp R
Drug Dev Ind Pharm; 2003 Aug; 29(7):785-93. PubMed ID: 12906336
[TBL] [Abstract][Full Text] [Related]
12. Raloxifene encapsulated spanlastic nanogel for the prevention of bone fracture risk via transdermal administration: Pharmacokinetic and efficacy study in animal model.
Ansari MD; Shafi S; Pandit J; Waheed A; Jahan RN; Khan I; Vohora D; Jain S; Aqil M; Sultana Y
Drug Deliv Transl Res; 2024 Jun; 14(6):1635-1647. PubMed ID: 37996726
[TBL] [Abstract][Full Text] [Related]
13. Transdermal delivery of ketorolac.
Amrish C; Kumar SP
Yakugaku Zasshi; 2009 Mar; 129(3):373-9. PubMed ID: 19252396
[TBL] [Abstract][Full Text] [Related]
14. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement.
Aboofazeli R; Zia H; Needham TE
Drug Deliv; 2002; 9(4):239-47. PubMed ID: 12511202
[TBL] [Abstract][Full Text] [Related]
15. Transdermal Delivery of the Free Base of 3-Fluoroamphetamine: In Vitro Skin Permeation and Irritation Potential.
Jiang Y; Murnane KS; Blough BE; Banga AK
AAPS PharmSciTech; 2020 Mar; 21(3):109. PubMed ID: 32215773
[TBL] [Abstract][Full Text] [Related]
16. Skin Delivery and Irritation Potential of Phenmetrazine as a Candidate Transdermal Formulation for Repurposed Indications.
Jiang Y; Murnane KS; Bhattaccharjee SA; Blough BE; Banga AK
AAPS J; 2019 May; 21(4):70. PubMed ID: 31152318
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
Yang Z; Teng Y; Wang H; Hou H
Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
[TBL] [Abstract][Full Text] [Related]
18. Effects of chemical and physical enhancement techniques on transdermal delivery of 3-fluoroamphetamine hydrochloride.
Puri A; Murnane KS; Blough BE; Banga AK
Int J Pharm; 2017 Aug; 528(1-2):452-462. PubMed ID: 28633107
[TBL] [Abstract][Full Text] [Related]
19. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.
Elsheikh MA; Elnaggar YS; Gohar EY; Abdallah OY
Int J Nanomedicine; 2012; 7():3787-802. PubMed ID: 22888234
[TBL] [Abstract][Full Text] [Related]
20. The Sensitivity of In Vitro Permeation Tests to Chemical Penetration Enhancer Concentration Changes in Fentanyl Transdermal Delivery Systems.
Shin SH; Srivilai J; Ibrahim SA; Strasinger C; Hammell DC; Hassan HE; Stinchcomb AL
AAPS PharmSciTech; 2018 Oct; 19(7):2778-2786. PubMed ID: 30084070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
